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Palmas, Spain; and 4Division of Nephrology, Department of Medicine, Hospital Costa del Sol, Málaga, SpainIntroduction: Chronic kidney disease is a major public health problem. In the last decade, it has been
shown that the early stages of chronic kidney disease are associated with an inﬂammatory condition
involving an increased risk of cardiovascular morbidity and long-term mortality. In patients with chronic
kidney disease and more speciﬁcally those on hemodialysis, cardiovascular events are the most common
cause of death. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase
and may be an independent risk factor for endothelial dysfunction and cardiovascular disease.
Methods: We performed a cross-sectional analysis to identify factors that were associated with ADMA
such as certain medications related to cardiovascular disease in dialysis patients.
Results: Patients who were treated with paricalcitol had signiﬁcantly lower levels of ADMA (0.21  0.19
mmol/l) compared with those not treated with paricalcitol (0.42  0.35 mmol/l) (P ¼ 0.00027). Dividing ADMA
levels by quartiles, patients treated with paricalcitol were less likely to have very high level ADMA
(P¼ 0.014), whereas therewere no signiﬁcant differenceswith othermedications. Higher dose of paricalcitol
was also related to lower levels of ADMA noting an inverse correlation (r ¼ –0.36, P ¼ 0.013).
Discussion: Hemodialysis patients treated with paricalcitol presented signiﬁcantly decreased ADMA levels
compared with those who did not receive this treatment. Possible beneﬁcial effects in terms of cardio-
vascular morbidity and mortality by paricalcitol and its association with ADMA and nitric oxide synthesis
are unknown. Studies to conﬁrm this effect and determine the underlying pathophysiological mechanism
are necessary.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A symmetric dimethylarginine (ADMA) is anendogenous nitric oxide synthase inhibitor that
may be an independent risk factor for endothelial
dysfunction and cardiovascular disease.1 Patients with
and without established coronary heart disease and
elevated levels of serum ADMA have an increased risk
of acute coronary events compared with individuals
with lower ADMA levels.2–4 ADMA, which is signiﬁ-
cantly increased in end-stage renal disease (ESRD),5 isspondence: Nestor Oliva-Damaso, Division of Nephrology
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ved 23 March 2016; revised 6 October 2016; accepted 13
er 2016; published online 18 October 2016
International Reports (2016) -, -–-an endogenous inhibitor of nitric oxide.6,7 Inhibition of
nitric oxide synthesis in patients with ESRD may cause
vasoconstriction and hypertension, thereby resulting
in adverse cardiovascular outcomes.8–11 In hemodialy-
sis patients, plasma ADMA is a strong and independent
predictor of overall mortality and cardiovascular
outcome.9
Paricalcitol has demonstrated effects on endothelial
function and suppressing inﬂammation decreasing
levels of high-sensitivity C-reactive protein, tumor
necrosis factor-a, and interleukin-6 in hemodialysis
patients.12 High ADMA levels are a consequence of
endothelial dysfunction1 and the effects of paricalcitol
on ADMA levels have not been reported.
Certain drugs such as proton pump inhibitors have
been associated with the elevation of asymmetric1
CLINICAL RESEARCH E Oliva-Damaso et al.: ADMA and Paricalcitoldimethylarginine levels,13 whereas other drugs
have been associated with a reduction of ADMA levels
in several reports, such as certain angiotensin
converting enzyme inhibitors and angiotensin recep-
tor blockers,14–16 metformin,17 rosiglitazone,17,18 or
rosuvastatin.19
We report a study designed to evaluate the rela-
tionship between levels of ADMA with survival in
hemodialysis patients and a cross-sectional analysis to
study the association between levels of ADMA and the
use of drugs that have demonstrated a reduction of
cardiovascular disease in dialysis patients, such as
statins, aspirin, angiotensin converting enzyme
inhibitors and/or angiotensin receptor blockers, and
paricalcitol.
METHODS
Study Design, Setting, and Patients
We performed a cross-sectional observational study in
patients on chronic hemodialysis to evaluate the asso-
ciation of ADMA with medication as well as a pro-
spective study to evaluate ADMA with mortality. The
study was performed in the Hospital Universitario de
Gran Canaria Doctor Negrin, Gran Canaria, Spain,
between April 2011 and April 2014. Ninety-three
patients who underwent chronic hemodialysis treat-
ment (62.4% men and 37.6% women) were randomly
selected from a total of 231 patients. All patients were
being treated 3 times a week with standard bicarbonate
dialysis (Naþ 138 mmol/l, HCO3
 35 nnol/l, Kþ
1.5 mmol/l, Ca2þ 1.25 mmol/l, Mg2þ 0.75 mmol/l) with
1.7 or 2.1 polysulfone membrane dialyzers.
Patients continued with their usual treatment pre-
scribed for chronic diseases previously diagnosed.Table 1. Baseline characteristics of patients including totals and quartile
Total Quartile
Age (yr) 66 (19) 65 (20)
Sex (men) Men: 58 (62.4%) 15 (62.5
Dry weight (kg) 71.0  13.4 68.3  13
BMI (kg/m2) 25.7  4.7 24.1  4
BMI $ 30 kg/m2 Yes: 16 (17.2%) 2 (8.3)
Time in HD (mo) 53.1 (57.9) 46 (80)
Central venous catheter 15 (16.1%) 1 (4.2)
Charlson Comorbidity Index 4 (2) 3.5 (2)
Ethiology of CKD Diabetic nephropathy: 35 (37.6%) 10 (41.7
Nephroangioesclerosis: 6 (6.5%) 1 (4.2)
Polycystic kidney disease: 10 (10.8%) 4 (16.7
Glomerulonephritis: 13 (14%) 3 (12.5
Others: 21 (22.6%) 5 (20.8
Unknown: 8 (8.6%) 1 (4.2)
DM Yes: 42 (45.2%) 10 (41.7
ACEi/ARBs 22 (23.7%) 9 (37.5
Paricalcitol 37 (39.8%) 14 (58.3
Coronary arterial disease 23 (25.3%) 5 (20.8
Data are shown as mean (SD), median (interquartile range), or number of cases (percentage
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; BMI, body mass ind
2They had no changes on medication related to CKD
bone mineral disease for 2 months before the serum for
determination of ADMA levels was collected. No
changes were therefore made of paricalcitol or calcitriol
from 2 months before. No patients had treatment with
calcitriol or alphacalcidol. There were no signiﬁcant
differences between quartiles attending to cinacalcet or
phosphate binders (calcium and non–calcium-based
phosphate binders).
The protocol adhered to the ethical guidelines of our
hospital and this study was evaluated and accepted by
the Clinical Research Ethics Committee of the Hospital
Universitario de Gran Canaria Doctor Negrin, which
meets BPC (CPMP/ICH/135/95) standards and Spanish
laws (R.D. 223/2004). All patients enrolled in the study
received exhaustive information, and were asked for
their participation, signing the corresponding consent.
A review of medical records was conducted, as well
as computer databases used in the Nephrology
Department to collect data, including demographic,
anthropometric, physical examination, vital signs, and
biochemical data. At 36 months, a review of death
records was conducted. Finally, we proceeded to the
statistical analysis of the results.
The variables analyzed are deﬁned in Tables 1 and 2.
Laboratory
Samples of peripheral venous blood were obtained, the
ﬁrst dialysis day of the week (Monday or Tuesday),
after a minimum fasting period of 8 hours. Blood
samples were sent to the reference laboratory for
biochemical determinations. The samples for ADMA
determination were kept at –80C until the analysis of
ADMA was performed.s of ADMA levels (mmol/l)
1 Quartile 2 Quartile 3 Quartile 4 P value
64 (10) 70 (19) 74 (19) 0.15
) 14 (60.9) 16 (69.6) 13 (56.5) 0.86
.5 70.8  11.8 75.7  12.1 69.5  69.5 0.26
.3 25.7  5.0 26.9  4.0 26.2  5.0 0.19
4 (17.4) 4 (17.4) 6 (26.1) 0.475
46.7 (44.1) 58.2 (61.2) 53.9 (54.8) 0.48
4 (17.4) 4 (17.4) 6 (26.1) 0.21
4 (2) 5 (2) 3.5 (2) 0.46
) 7 (30.4) 8 (34.8) 10 (43.5) 0.82
0 (0) 4 (17.4) 1 (4.3)
) 3 (13) 2 (8.7) 1 (4.3)
) 5 (21.7) 3 (13) 2 (8.7)
) 6 (26.1) 4 (17.4) 6 (26.1)
2 (8.7) 2 (8.7) 1 (4.3)
) 11 (47.8) 9 (39.1) 12 (52.2) 0.82
) 4 (17.4) 5 (21.7) 4 (17.4) 0.348
) 11 (47.8) 8 (34.8) 4 (17.4) 0.026
) 5 (22.7) 6 (26.1) 7 (31.8) 0.87
frequency), as appropriate.
ex; CKD, chronic kidney disease; DM, diabetes mellitus; HD, hemodialysis.
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Table 2. Differences between groups with and without paricalcitol
treatment
Total
(n [ 93)
Non--paricalcitol-
treated group
(n [ 56)
Paricalcitol-treated
group (n [ 37)
P
value
Categorical variables
Sex (men) 57 (61.3) 34 (59.6%) 23 (40.4%) 1
Diabetes 42 (41.2) 31 (73.8%) 11 (26.2%) 0.019
ARB/ACE inhibitors 22 (23.7) 13 (59.1%) 9 (40.9%) 1
Aspirin 62 (66.7) 40 (64.5%) 22 (35.5%) 0.27
Statins 65 (69.9) 39 (60%) 26 (40%) 1
Blood pressure
medication
56 (60.2) 33 (58.9%) 23 (41.1%) 0.83
Continuous variables
Age (yr) 64.7  13.1 66.2  13.0 62.4  13.1 0.17
BMI (kg/m2) 25.7  4.7 25.6  4.6 25.9  4.8 0.78
Duration of dialysis
treatment (mo)
65.3  43.9 58  33.4 74.7  55.2 0.12
Basal glucose
(mg/dl)
110.4  65.7 111.8  57.5 108.4  77.1 0.82
Cholesterol (mg/dl) 143.3  31.6 146.4  34.7 138.7  26.2 0.26
Albumin (g/dl) 3.8  0.3 3.8  0.4 3.8  0.3 0.45
Ca (mg/dl) 9.2  0.6 9.2  0.5 9.1  0.7 0.36
P (mg/dl) 5.1  1.4 5.2  1.6 4.9  1.1 0.31
PTHi (pg/ml) 445.6  394.8 417.2  375.7 487.5  423.2 0.41
PTHi nichols 310.8  307.8 292.8  293 336.3  330.1 0.52
25 OH vitamin D
(ng/dl)
16.6  12.5 14.4  7.9 19.8  16.8 0.08
Homocysteine
(mmol/l)
31.9  22.9 32  22.2 31.76  24.3 0.96
Kt/V Daugirdas 1.5  0.4 1.6  0.4 1.5  0.4 0.76
Data are shown as mean (SD), median (interquartile range) or number of cases (per-
centage frequency), as appropriate.
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; BMI, body
mass index; PTH, parathyroid hormone.
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ADMA levels were determined by high-performance
liquid chromatography (HPLC), a method using
derivatization with o-phthalaldehyde based on the
procedure described by Chu et al.,20 after removal of
plasma samples with carboxylic acid solid-phase
extraction cartridges. Increasing concentrations of
ADMA were spiked into the pooled blank plasma to
achieve the concentrations of ADMA. After the addi-
tion of internal standard, standards were subjected to
solid-phase extraction, derivatization, and chromatog-
raphy as already mentioned. Because there were
endogenous ADMA, symmetric dimethylarginine, and
arginine in the blank plasma, the actual peak heights of
spiked standards were calculated by subtracting the
peak heights of analytes in the blank plasma from the
peak heights of analytes in the spiked standards.
Calibration curves were constructed by plotting the
ratios of the actual peak height of analyte over internal
standard versus analyte concentration. For the analysis
of plasma samples, a calibration curve was performed
in each run. Paricalcitol was administrated in dialysis
sessions and intravenously.Kidney International Reports (2016) -, -–-Reagents
ADMA, o-phtaldialdehyde, 2-mercaptoethanol, tri-
chloroacetic acid, triethylamine, boric acid, and sodium
acetate were purchased from Sigma Chemical Co.
(St. Louis, MO). Acetonitrile (HPLC grade), methanol
(HPLC grade), potassium hydroxide (KOH), and tetra-
hydrofuran were from Merck-España (Madrid, Spain).
Equipment
For our study, we used a VARIAN PS230 chromato-
graph (1644 series) and reverse phase-HPLC.
Statistical Analysis
The sample was described by means of frequencies and
percentages for qualitative variables and mean  SD or
median (interquartile range [IQR] ¼ Q3–Q1) for quan-
titative variables, depending on the setting of the
variables to the normal distribution. Survival was
evaluated using Cox regression analysis using ADMA
variable raw and adjusted for other variables,
including age variable dependent on time. No variable
selection algorithm was used. The Kaplan-Meier
method was applied to evaluate the survival
comparing the group consisting of the upper quartile of
ADMA (P > 75, Q4) against the rest. The curves were
compared with the log-rank test. Death probability at
the end of the study using a logistic regression model
was calculated. Time to event was considered from the
moment of ADMA determination until event (death) or
end of the study. No patients were lost from follow-up.
To evaluate the association between paricalcitol with
categorical variables, the Fisher exact test was used.
The relationship between ADMA and other variables
was explored by comparing ADMA means by analysis
of variance (for more than 2 groups), the t test, or the
Mann-Whitney U test (for 2 variables, according to the
distribution). In the t test, the Welch correction was
performed when the Levene homogeneity test of vari-
ance was signiﬁcant. Multiple linear regression was
also performed to analyze ADMA with other variables
to study effect measure modiﬁers and confounders.
Likewise a robust regression method (bootstrapping)
was performed to compare with the multiple linear
regression analysis.
To evaluate the association of ADMA with contin-
uous quantitative variables, scatter plot diagrams were
done and Pearson correlation coefﬁcient was performed
when there was linearity in the relationship. Finally,
ADMA was categorized as quartiles, comparing the
upper quartile with the highest concentration of
ADMA to the rest. The signiﬁcance level was estab-
lished at a ¼ 0.05.
The statistical program used was R Core Team (2014).3
Figure 2. Quartile 1 shows that more patients were treated with
paricalcitol and therefore they have lower levels of ADMA (mmol/l).
Patients with higher levels of ADMA were less likely to receive
treatment with paricalcitol (P ¼ 0.014). ADMA, asymmetric
dimethylarginine.
CLINICAL RESEARCH E Oliva-Damaso et al.: ADMA and ParicalcitolRESULTS
Ninety-three patients who underwent chronic hemo-
dialysis treatment (62.4% male) were randomly
selected from a total of 231 patients, and had an average
age of 64.7  13.1 years. Of them, 45.2% were diabetic,
and diabetic nephropathy was the most frequent cause
of ESRD (37.6%). The median time in dialysis treatment
was 53.1 months (IQR ¼ 57.9). The baseline charac-
teristics and frequency of medications are shown in
Table 1.
Plasma ADMA concentrations were measured,
showing a median concentration of 0.2 mmol/l (IQR ¼
0.48). Patients treated with paricalcitol had signiﬁ-
cantly lower ADMA levels (0.21  0.19 mmol/l vs. 0.42
 0.35 mmol/l; P ¼ 0.00027), as shown in Figure 1.
Patients were also divided into 4 quartiles according
to ADMA levels. The patients in the highest ADMA
concentration quartile were compared with those in the
other 3 quartiles (median of 0.64 mmol/l, IQR ¼ 0.06 vs.
median of 0.18 mmol/l, IQR ¼ 0.18). We compared the
number of patients in the highest quartile (Q4) and the
treatment patients received, noting that those who
received paricalcitol were signiﬁcantly less likely to be
in the very high level ADMA group (P ¼ 0.014). We
did not observe statistical differences between ADMA
levels and the use of angiotensin receptor blocker/
angiotensin converting enzyme inhibitors (P ¼ 0.15),
statins (P ¼ 0.25), or aspirin (P ¼ 0.93). The distribu-
tion of patients treated with paricalcitol with lower
levels of plasma ADMA compared with those not
treated with paricalcitol who had higher levels is rep-
resented in Figure 2.
The clinical and laboratory characteristics of patients
who were treated with paricalcitol (n ¼ 37) and
patients who were not treated with paricalcitol (n ¼ 56)
are shown in Table 2. There were no signiﬁcant dif-
ferences in age, sex, treatment with angiotensinFigure 1. The difference between ADMA levels (mmol/l) in patients
treated with paricalcitol compared with those who did not receive
paricalcitol. ADMA, asymmetric dimethylarginine.
4receptor blockers/angiotensin converting enzyme
inhibitors, aspirin or statins, body mass index, time on
dialysis, cholesterol, albumin, serum calcium, phos-
phate, parathyroid hormone (PTH), or vitamin D levels
between patients who were or were not on paricalcitol
at the time that the ADMA levels were obtained. Pa-
tients on paricalcitol had a lower prevalence of diabetes
than those not on this medication (29.7% vs. 55.3%;
P ¼ 0.019). ADMA levels were higher among diabetics
(0.38  0.41 mmol/l) compared with nondiabetics (0.31
 0.25 mmol/l), but this was not statistically signiﬁcant.
However, in the diabetic patients subgroup, those who
received paricalcitol had lower ADMA levels compared
with those who did not receive paricalcitol with sta-
tistical differences (P ¼ 0.0342). In the nondiabetic
patients subgroup also, it was conﬁrmed that those
treated with paricalcitol had lower ADMA levels than
those not treated with paricalcitol with a signiﬁcant
difference (P ¼ 0.0157), as shown in Figure 3.
In addition, there was an inverse correlation
between the weekly dose of paricalcitol and ADMA
levels with a Pearson’s and Spearman’s correlationKidney International Reports (2016) -, -–-
Figure 3. ADMA (mmol/l) levels of patients treated with paricalcitol
and those not treated with paricalcitol in the nondiabetic and dia-
betic subgroups. ADMA, asymmetric dimethylarginine.
E Oliva-Damaso et al.: ADMA and Paricalcitol CLINICAL RESEARCHcoefﬁcient between paricalcitol and ADMA of –0.36
(P ¼ 0.013; Figure 4) and –0.46 (P ¼ 0.001), respec-
tively. In the multivariable analysis, paricalcitol, age,
and serum PTH levels were associated with ADMA
levels; paricalcitol tended to show a signiﬁcant associ-
ation (Table 3).
At 36 months’ follow-up, we observed an all-cause
mortality of 30.1% with 28 deaths, 15 of which were
due to cardiovascular events. In a model that only
includes ADMA (as a continuous variable) as a predictorFigure 4. Inverse correlation between paricalcitol dose (mcg per week)
dimethylarginine.
Kidney International Reports (2016) -, -–-of mortality, its value is signiﬁcant (P ¼ 0.0033), but
when other variables (age, sex, hypertension, and dia-
betes mellitus) are included in the model, ADMA looses
signiﬁcance as a mortality predictor (see Supplementary
Figures S1–S3). We did not ﬁnd the association between
ADMA levels and cardiovascular cause mortality.
DISCUSSION
Hemodialysis patients on paricalcitol treatment had
lower plasma ADMA levels according to our study.
ADMA is signiﬁcantly increased in ESRD.5 Our study
shows that dialysis patients treated with paricalcitol
had signiﬁcantly lower ADMA concentrations than
those not treated with paricalcitol. ADMA, an endog-
enous methylated arginine analog, results from protein
turnover, and its metabolism is facilitated by dime-
thylarginine dimethylaminohydrolase-1 and -2 iso-
forms. ADMA inhibits nitric oxide synthases, which
may in part explain the impaired vasorelaxation,
elevated inﬂammation, and reduced angiogenesis re-
ported in patients and animal models of CKD.21 Zoccali
et al.9 identiﬁed the plasma concentrations of ADMA as
a predictor of mortality and cardiovascular disease in
patients with chronic renal failure. On the other hand,
data related to different medications that modify levels
of ADMA have been reported.13,14,19,22–24 Our study is
the ﬁrst, to our knowledge, to establish a link between
ADMA and paricalcitol in hemodialysis patients.
Paricalcitol (19-nor-1,25-dihydroxyvitamin D2), a
vitamin D analog with less hypercalcemic effect than
calcitriol,25 may provide a survival beneﬁt for patientsand serum ADMA levels (r ¼ –0.36, P ¼ 0.013). ADMA, asymmetric
5
Table 3. Factors associated with ADMA levels: multivariate
regression analysis using ADMA levels as a dependent variable
Independent
variables b-coefﬁcient SE
Beta
(standardized) 95% CI P value
Age (yr) 5.81 2.26 0.25 1.32, 10.31 0.012
Paricalcitol: yes –183.52 60.56 –0.3 –303.93,
–63.11
0.003
PTHi (ng/l) 0.16 0.07 0.21 0.01, 0.31 0.034
ADMA, asymmetric dimethylarginine; CI, conﬁdence interval; PTH, parathyroid
hormone.
CLINICAL RESEARCH E Oliva-Damaso et al.: ADMA and Paricalcitolwith CKD, which is independent of the calcium and
parathyroid hormone.26,27 Paricalcitol could have a sur-
vival advantage in dialysis patients, possibly due to its
ability to suppress PTH levels with less severe
increments in serum calcium and phosphate.28 Although
paricalcitol reduces circulating bone turnover markers
and PTH levels, the potential mechanism by which
paricalcitol exerts its beneﬁcial effect is not yet fully
clariﬁed. Recent studies report that this mechanism
seems unrelated to ﬁbroblast growth factor-23, as par-
icalcitol therapy increases the levels of ﬁbroblast growth
factor-23.29 Paricalcitol has demonstrated effects on
endothelial function and suppressing inﬂammation
decreasing levels of high-sensitivity C-reactive protein,
tumor necrosis factor-a, and interleukin-6 in hemodial-
ysis patients,12 but the effects of paricalcitol on ADMA
require future studies.
Although our study was designed as a prospective
study, conﬁrming, like in other studies, that in our
cohort ADMA levels predict overall mortality,9,30–36 we
mainly present cross-sectional results that we report as
the main limitation. To conclude, we found that in
hemodialysis patients, those treated with paricalcitol
had lower levels of plasma ADMA concentrations.
Future studies are needed to evaluate the relationship
between ADMA and paricalcitol in ESRD and other
stages of CKD. The effects paricalcitol can have on
ADMA levels and the underlying endothelial function
mechanisms still need to be studied.
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SUPPLEMENTARY MATERIAL
Figure S1. Kaplan-Meier survival analysis evaluating the
correlation between ADMA and all-cause mortality. Hazard
ratio: 2.062; Conﬁdence interval (CI) ¼ [0.95; 4.47].6Figure S2. Relationship between ADMA (mmol/l) and
medications used in dialysis patients.
Figure S3. Histogram showing ADMA levels (mmol/l) in
patients treated with paricalcitol (red line) or not (black
line). Patients treated with paricalcitol (in red) are
grouped at the beginning of the graph, where ADMA
levels are lower, whereas those patients not receiving
paricalcitol (in black) are more evenly distributed along
the vertical axis.
Supplementary material is linked to the online version of
the paper at www.kireports.org.
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